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DOI 10.1016/j.ccr.2011.03.002SUMMARYChronic pancreatitis is a well-known risk factor for pancreatic ductal adenocarcinoma (PDA) development in
humans, and inflammation promotes PDA initiation and progression in mouse models of the disease.
However, the mechanistic link between inflammatory damage and PDA initiation is unclear. Using a Kras-
driven mouse model of PDA, we establish that the inflammatory mediator Stat3 is a critical component of
spontaneous and pancreatitis-accelerated PDA precursor formation and supports cell proliferation, meta-
plasia-associated inflammation, and MMP7 expression during neoplastic development. Furthermore, we
show that Stat3 signaling enforces MMP7 expression in PDA cells and that MMP7 deletion limits tumor
size and metastasis in mice. Finally, we demonstrate that serum MMP7 level in human patients with PDA
correlated with metastatic disease and survival.INTRODUCTION
It is generally believed that pancreatic ductal adenocarcinoma
(PDA) initiation commonly occurs with metaplastic conversion of
normal cells to noninvasive ductal precursors such as pancreatic
intraepithelial neoplasia (PanIN). Gain-of-function mutations in
the Kras gene are nearly universal in human PDA (Almoguera
et al., 1988), and pancreas-specific expression of mutant Kras in
mice recapitulates the human PanIN-to-PDA sequence (Hingorani
et al., 2003), suggesting that Krasmutationmay represent an initi-
ating event. Although both PanINs and PDA express ductal
markers, mouse models have recently revealed that mutant Kras
can reprogram acinar cells to enter the PanIN/PDA lineage in aSignificance
Patients with pancreatic cancer have a less than 5% 5-year su
include a lack of clear understanding of disease pathogenesis,
of the tumor leading to early metastasis, and a lack of effectiv
MMP7 signaling axis as a key mediator in PDA biology both in
tive target for future therapeutic development. Furthermore, ser
of metastatic disease, therefore providing physicians and patiprocess termed acinar to ductal metaplasia (ADM) (De La et al.,
2008; Guerra et al., 2007; Habbe et al., 2008; Morris et al., 2010).
Chronic pancreatitis has been identified as risk factor for PDA
development in humans (Lowenfels et al., 1993) and has been
shown to significantly accelerate PanIN and PDA development
in Kras-driven mouse models of PDA (Guerra et al., 2007). In
addition acute pancreatitis can progress to chronic pancreatitis
in human patients, often under conditions in which environ-
mental insults such as alcohol and cigarette smoking are present
(Lankisch et al., 2009). Notably, recent reports have shown that
acute pancreatitis also markedly accelerates PanIN and PDA
development in Kras-driven mouse models of PDA (Carriere
et al., 2009; Morris et al., 2010).rvival rate after diagnosis. Obstacles to improving outcomes
poor early detection tools, the inherently aggressive biology
e chemotherapeutics. In this study we establish the Stat3-
the early and late-disease process, thus providing an attrac-
umMMP7 levels in human patients with PDAwere predictive
ents with a tool for guiding treatment plans.
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Stat3 and MMP7 in Pancreatic Ductal AdenocarcinomaMouse models of acute pancreatitis have revealed that the
exocrine pancreas possesses remarkable regenerative capacity
after inflammatory damage. In response to acute pancreatitis
induced by the cholecystokinin analog caerulein, acini tran-
siently dedifferentiate into duct-like structures that express
embryonic factors characteristic of pancreatic embryonic
progenitors. In the absence of further damage, redifferentiation
into functional acinar cells occurs rapidly within 1 week of caer-
ulein treatment (De La andMurtaugh, 2009; Fendrich et al., 2008;
Jensen et al., 2005; Morris et al., 2010; Siveke et al., 2008). In
contrast, mutant Kras compromises the ability of acinar cells to
regenerate following acute pancreatitis and locks damaged cells
in a persistently dedifferentiated, ductal state that can rapidly
give rise to PanINs (De La and Murtaugh, 2009; Morris et al.,
2010). Thus, whereas pancreatitis provides a permissive envi-
ronment for Kras-driven neoplasia, the molecular mechanisms
supporting this state remain largely unknown.
Signal transducer and activator of transcription 3 (Stat3) inte-
grates signals from cytokines and growth factors into transcrip-
tional responses in target cells and may serve as a mediator of
inflammation-associated processes, such as pancreatitis-driven
PanIN development. Stat3 mediates a complex spectrum of
cellular responses including inflammation, cell proliferation,
and apoptosis (Levy and Lee, 2002). Stat3 also supports inflam-
mation-associated tumorigenesis in the colon (Bollrath et al.,
2009; Grivennikov et al., 2009), stomach (Ernst et al., 2008),
and lung (Li et al., 2007). In the pancreas, Stat3 is aberrantly acti-
vated in human PDA, controls proliferation in PDA cell lines
(Scholz et al., 2003), and is implicated in amousemodel of acinar
to ductal reprogramming driven by persistent exocrine expres-
sion of the key pancreatic transcription factor Pdx1 (Miyatsuka
et al., 2006). However, to our knowledge, the role of Stat3 in
Kras-dependent initiation of the PanIN/PDA lineage has not
been investigated.
Matrix metalloproteinase 7 (MMP7), also known as matrilysin,
is a member of a family of zinc-dependent endopeptidases.
MMP7 is expressed predominantly in epithelial cells of glandular
tissue, unlike other MMPs, which are often stromally derived
(Wilson et al., 1997). MMP7 is overexpressed in PanINs and
PDA (Crawford et al., 2002; Yamamoto et al., 2001) and corre-
lates with decreased survival and possibly tumor size, lymph
node involvement, and distant metastasis (Fukushima et al.,
2001; Jones et al., 2004; Yamamoto et al., 2001). Significantly,
MMP7-deficient mice are resistant to acinar apoptosis and
ADM in an obstructive-pancreatitis model (Crawford et al.,
2002), and MMP7 is required for in vitro ADM driven by EGF
signaling (Sawey et al., 2007). Other in vitro studies suggest
that MMP7 is also involved in disease progression by dictating
the invasive and metastatic capacity of PDA cells (Yamamoto
et al., 2001). Interestingly, MMP7 is induced through a Stat3-
dependent mechanism in prostate and breast cancer cell lines
(Udayakumar et al., 2002; Yuan et al., 2008), but, to our knowl-
edge, a role for MMP7 in Kras-driven PDA or whether the
Stat3-MMP7 axis is maintained in PDA progression has not
been investigated.
In this study we investigated the in vivo role of Stat3 in initiating
thePanIN/PDA lineage in the setting of pancreatitis, tested for the
presence of the Stat3-MMP7 signaling in the pancreas, and
determined the role of MMP7 in PDA initiation and progression.442 Cancer Cell 19, 441–455, April 12, 2011 ª2011 Elsevier Inc.RESULTS
Persistent Stat3 Activation Is a Hallmark of Kras-Driven
Ductal Metaplasia in Response to Acute Pancreatitis
To determine if Stat3 signaling is involved in the pancreatic
response to inflammatory damage, we audited pancreatic
Stat3 activation levels in response to acute pancreatitis. We
induced acute pancreatitis with caerulein as described previ-
ously (Morris et al., 2010). Immunohistochemistry (IHC) revealed
no active, phosphorylated Stat3 (p-Stat3) in control adult
pancreas. In contrast, p-Stat3 was widely observed in the
damaged exocrine compartment of control mice 1 day after
caerulein injection. Corresponding with acinar regeneration,
p-Stat3 staining was again generally absent in the exocrine
pancreas by 7 days after caerulein treatment (Figures 1A–1D).
Western blotting for p-Stat3 in pancreas lysates and quantitative
RT-PCR (qPCR) forSocs3, a Stat3 target gene, revealed a similar
pattern of transient activation (Figures 1I and 1J), suggesting that
Stat3 signaling is active during pancreatic regeneration but
quiescent in the undamaged pancreas.
We have previously shown that mutant Kras blocks acinar
regeneration in favor of ductal reprogramming and PanIN forma-
tion after acute pancreatitis (Morris et al., 2010). Therefore, we
examined Stat3 signaling during pancreatitis-induced PanIN
development in mice expressing a conditional, constitutively
active form of Kras (KrasG12D) (Hingorani et al., 2003) targeted
to pancreatic progenitors under the control of the Ptf1a promoter
(Ptf1a-Cre) (Kawaguchi et al., 2002). In 6-week-old Ptf1a-Cre;
KrasG12Dmice treated with PBS, p-Stat3 expression was absent
in most morphologically normal acini and ducts but was readily
detectable in spontaneously formed PanINs, directly associated
stromal cells, and occasionally in acini surrounding the PanINs
(Figure 1E). Similar to control mice, Stat3 activation was widely
observed in epithelial cells in Ptf1a-Cre; KrasG12D mice 1 day
after caerulein treatment (Figures 1F, 1I, and 1K). However, in
contrast to control mice, Ptf1a-Cre; KrasG12D animals displayed
persistent Stat3 activation 7 and 21 days postinjection (Figures
1G–1I and 1K) in the setting of metaplastic ducts and PanIN
lesions, suggesting a role for Stat3 in reprogramming normal
acinar cells into PDA precursors following inflammatory damage.
One possible explanation for persistent Stat3 activation in
caerulein-treated Ptf1a-Cre; KrasG12D mice is enforced expres-
sion of factors known to activate the JAK/STAT cascade.
Previous studies have indicated an obligate role for IL-6 in Ras
transformation, and that oncogenic Ras supports Stat3 activa-
tion by inducing the secretion of IL-6 (Ancrile et al., 2007). Similar
to Stat3 signaling, we found that IL-6 expression was only tran-
siently upregulated after caerulein injection in wild-type mice,
whereas IL-6 was persistently expressed in Ptf1a-Cre; KrasG12D
animals (see Figure S1 available online). Therefore, persistent
expression of IL-6may be involved in prolonged Stat3 activation
in Ptf1a-Cre; KrasG12D mice following inflammatory insults.
Pancreatic Epithelial Stat3 Deletion Inhibits Both
Spontaneous and Pancreatitis-Induced PanIN
Formation
To establish if the Stat3 pathway is functionally relevant during
PDA precursor formation, we generated mice expressing
KrasG12D and conditional Stat3 alleles (Ptf1a-Cre; KrasG12D;
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Figure 1. Persistent Stat3 Activation after Pancreatitis in Setting of Activated Kras
(A–H) IHC for p-Stat3 in control (A–D) or Ptf1a-Cre; KrasG12D pancreata (E–H) after PBS and caerulein treatments. (A) PBS. (B) One day post-caerulein. (C) Seven
days post-caerulein. (D) Twenty-one days post-caerulein. (E) PBS. Stat3 is activated only in the epithelial cells of spontaneously formed PanINs and surrounding
stromal cells. (F) One day post-caerulein. (G) Seven days post-caerulein. Stat3 activation is maintained in metaplastic ducts in mice with activated Kras.
(H) Twenty-one days post-caerulein. Stat3 activation is maintained in PanINs in mice with activated Kras.
(I) Stat3 target gene Socs3 expression in pancreata by qPCR after caerulein injection. Socs3 expression is maintained in mice with activated Kras signaling 7 and
21 days after caerulein. Mean ± SD (n = 3). *p < 0.05 and **p < 0.01. N.S., not significant.
(J) Western blot. p-Stat3 is observed only 1 day post-caerulein in control pancreata.
(K) Western blot. Sustained aberrant p-Stat3 post-caerulein in Ptf1a-Cre; KrasG12D pancreata. Scale bars, 50 mm.
See also Figure S1.
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Stat3 and MMP7 in Pancreatic Ductal AdenocarcinomaStat3f/f) (Takeda et al., 1998). At both birth and adulthood
(6 weeks), Ptf1a-Cre; Stat3f/f pancreata appeared normal, indi-
cating that pancreatic Stat3 signaling was dispensable for
pancreas development (data not shown). We analyzed 6-week-
old Ptf1a-Cre; KrasG12D and Ptf1a-Cre; KrasG12D; Stat3f/f mice
treated with PBS. Although we detected occasional PanINs in
Ptf1a-Cre; KrasG12D; Stat3f/f mice, the pancreatic area replaced
by lesions staining with Alcian blue, which is a marker of intes-
tinal mucin accumulation that characterizes human PanINs,
was significantly smaller when compared to Ptf1a-Cre; KrasG12Dmice (Figures 2A–2C). These data suggest that Stat3 deletion
interferes with Kras-driven spontaneous PanIN formation and
that Stat3 signaling plays an intrinsic role in PanIN development
in the absence of inflammatory insults.
Next, we investigated the role of epithelial Stat3 signaling on
Kras-driven PanIN formation in the setting of acute pancreatitis.
By 7 days after caerulein injection, the exocrine compartment
of Ptf1a-Cre; KrasG12D mice was nearly completely replaced by
fibrosis and ductal structures (Figure 2D), as evident by rare
expression of the acinar marker amylase (Figure 2H), andCancer Cell 19, 441–455, April 12, 2011 ª2011 Elsevier Inc. 443
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Figure 2. Stat3 Deletion Protects Against Spontaneous and Acute Pancreatitis-Accelerated PanIN Formation
Mice with activated Kras with or without Stat3 signaling (Ptf1a-Cre; KrasG12D and Ptf1a-Cre; KrasG12D; Stat3f/f, respectively), were injected with PBS (A–C) or
caerulein (D–V) and sacrificed either 7 or 21 days postinjection. The following stains were performed.
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Stat3 and MMP7 in Pancreatic Ductal Adenocarcinomawidespread expression of the ductmarker cytokeratin 19 (CK 19)
(Figure 2L). Ductal structures observed in Ptf1a-Cre; KrasG12D
mice 21 days after caerulein frequently stained positive with
Alcian blue (Figure 2T). In contrast, pancreata of Stat3-deficient
mice treated with caerulein did not display gross fibrosis at
necropsy, maintained dramatically more amylase-positive
parenchyma (Figures 2E, 2G, 2I, and 2K), and displayed fewer
CK 19-positive duct structures (Figures 2M and 2O). The area
of pancreas replaced by Alcian blue-positive lesions was also
significantly reduced in Stat3-deficient mice (Figures 2T–2V).
Although the frequency of PanINs was significantly different
between the genotypes, PanINs observed in both genotypes
were of equivalently low grades (PanIN 1A and 1B). As expected,
Stat3 activation was maintained in metaplastic ducts in
Ptf1a-Cre; KrasG12D mice at both 7 and 21 days postinjection
but was only observed in stromal cells surrounding PanIN lesions
and areas of ductal metaplasia, but not in epithelial cells of acini,
metaplastic ducts, or PanINs in Ptf1a-Cre; KrasG12D; Stat3f/f
mice (Figures 2P–2S). Given that chronic pancreatitis is a signifi-
cant risk factor for PDA in humans, we also tested the effects of
chronic pancreatitis and found similarly protective effects of
Stat3 deletion (Figures S2A–S2R). Summarily, these data
establish Stat3 as a critical component of the permissive envi-
ronment provided by pancreatitis to drive Kras-dependent
PanIN formation.
We next used a cell culture model of acinar to ductal dediffer-
entiation to ask whether Stat3 mediates ductal reprogramming
of acinar cells in a cell autonomous manner. Briefly, acinar
clusters isolated from adult mice embedded in collagen I trans-
differentiate into ductal structures in response to the EGF ligand,
TGF-a (Means et al., 2005; Miyamoto et al., 2003). In support of
our in vivo data, we found that Ptf1a-Cre; Stat3f/f acinar explants
formed significantly fewer CK19-positive ductal structures
after TGF-a treatment, as compared to control acinar explants,
suggesting that Stat3 contributes to acinar to ductal dedifferen-
tiation in part through cell-autonomous mechanisms in vitro
(Figures S2S–S2W).
To determine the long-term effects of Stat3 deletion on Kras-
driven neoplasia, we analyzed Ptf1a-Cre; KrasG12D and Ptf1a-
Cre; KrasG12D; Stat3f/f 8 months after acute pancreatitis.
Although no PDA was found in either group, Ptf1a-Cre; KrasG12D
mice appeared to have marked pancreatic exocrine insuffi-
ciency, as demonstrated by steatorrhea and significant loss of
body weight (Figures S2X–S2F0). Histology revealed that the
pancreatic epithelium was replaced almost entirely by PanINs.
In contrast, Stat3-deficient mice maintained body weight
comparable to controls, did not have steatorrhea, and retained
significantly more normal exocrine parenchyma than Ptf1a-Cre;(A and B) Alcian blue stain showing spontaneously formed PanINs.
(C) Alcian blue-positive lesion in total pancreas area of Ptf1a-Cre; KrasG12D (n =
(D–G) H&E. Fewer ductal and more acinar structures are observed in Stat3-defic
(H–K) Amylase. Stat3-deficient mice retained larger areas of amylase-expressing
(L–O) CK19. Mice with Stat3-intact display more CK19-positive ductal structures
(P–S) p-Stat3.
(T–U) Alcian blue stain, 21 days post-caerulein.
(V) Alcian blue-positive lesion in total pancreas area of Ptf1a-Cre; KrasG12D and
100 mm.
See also Figure S2.KrasG12D animals (Figures S2X–S2F0). Thus, the protective effect
of Stat3 deletion persists even months after acute damage.
Notably, PanIN 1B was the highest grade of lesion seen in either
genotype, suggesting that additional molecular events critical to
PanIN and PDA progression, such as the loss of tumor
suppressor genes, had not yet occurred over the course of our
aging experiments.
Stat3 Supports Persistent Cell Proliferation duringKras-
Driven PanIN Development following Acute Pancreatitis
Activated Stat3 signaling has been shown to regulate cellular
proliferation. To determine whether pancreatic Stat3 deletion
affects cell proliferation during Kras-driven metaplasia and
PanIN development after pancreatitis, we determined the prolif-
erative index of ductal cells, acinar cells, and PanIN lesions. We
found that there were significantly more amylase+/Ki67+ acinar
cells 2 days after caerulein and significantly more CK19+/Ki67+
ductal cells 2 and 7 days after caerulein in Ptf1a-Cre; Kras
mice compared to Ptf1a-Cre; KrasG12D; Stat3f/f animals (Figures
3A–3P). Thus, loss of Stat3 impairs proliferation during Kras-
driven pancreatic metaplasia. In contrast the proliferative
capacity of the few lesions positive for Alcian blue observed in
Ptf1a-Cre; KrasG12D; Stat3f/f animals was not altered when
compared to controls (Figures 3Q–3X). Staining for cleaved cas-
pase-3 showed that there were few apoptotic cells in all three
genotypes at both time points (data not shown), suggesting
that contribution of apoptosis is relativelyminimal during pancre-
atitis-promoted ductal reprogramming. Collectively, these data
demonstrate that Stat3 supports persistent cell proliferation
that characterizes Kras-dependent acinar metaplasia and PanIN
formation.
Stat3 Contributes to Inflammation Associated
with Kras-Driven Metaplasia after Injury
Because Stat3 is a critical mediator of inflammation during
neoplasia (Yu et al., 2009), we used FACS analysis to evaluate
whether Stat3 deletion altered the initial inflammatory response
during Kras-driven metaplasia following injury. One day after
caerulein injection, the percentage of total infiltrating immune
cells (CD45+ cells) was higher in Ptf1a-Cre; KrasG12D pancreata
compared to tissue from control and Ptf1a-Cre; KrasG12D;
Stat3f/f mice (Figure 4A). Additionally, an increase in the CD11b+
Gr1+ myeloid subset (known to contain myeloid-derived
suppressor cells and immature myeloid cells), as well as an
increased trend in infiltrating B (B220+) and T (Thy1.2+) lympho-
cytes, was seen in Ptf1a-Cre; KrasG12D mice compared to both
control and Stat3-deficient mice (Figures S3A–S3G). Although
additional analysis is necessary to refine the identity and function6) and Ptf1a-Cre; KrasG12D; Stat3f/f (n = 3) mice. Mean ± SD. **p < 0.01.
ient mice.
epithelium.
.
Ptf1a-Cre; KrasG12D; Stat3f/f mice. Mean ± SD (n = 3). **p < 0.01. Scale bars,
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Figure 3. Stat3 Supports Cell Proliferation during Kras-Driven PanIN Development following Acute Pancreatitis
Costaining of Ki67 with amylase (A–F), CK 19 (I–N), or Alcian blue (Q–V) in pancreata from control, Ptf1a-Cre; KrasG12D, and Ptf1a-Cre; KrasG12D; Stat3f/fmice 2 or
7 days postinjection. (A–C, I–K, and Q–S) Two days post-caerulein. (D–F, L–N, and T–V) Seven days post-caerulein. Quantification of double-positive cells
displaying Ki67 with amylase (G and H), cytokeratin19 (O and P), or Alcian blue (W and X), per 4003 field. Mean ± SD (n = 3). **p < 0.01. (G, O, and W) Two days
post-caerulein. (H, P, and X) Seven days post-caerulein. Scale bars, 50 mm.
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AC
B
Figure 4. Elimination of Pancreatic Stat3 Alters Inflammatory Response of Mutant Kras Mice after Injury
(A) The percentage of CD45+ immune cells among total live cells present in the pancreas was quantified using flow cytometry. Data from three independent
experiments are shown using control (n = 9), Ptf1a-Cre; KrasG12D (n = 8), and Ptf1a-Cre; KrasG12D; Stat3f/f (n = 5) mice.
(B) Relative expression of inflammatory mediators (IL-6, IL-11, IL-1b, Cox-2, ICAM1, Tnfa, and CCL2) in pancreata as measured by qPCR from control (n = 5),
Ptf1a-Cre; KrasG12D (n = 8), and Ptf1a-Cre; KrasG12D; Stat3f/f (n = 8) mice 1 day after caerulein injection. Mean ± SD.
(C) Relative expression of inflammatory mediators and Stat3 target genes (IL-6, IL-11, and Cox-2) in cultured primary acini isolated from wild-type and Ptf1a-Cre;
Stat3f/f mice 20 hr after treatment with BSA or 10 nM caerulein. Mean ± SD (n = 3). *p < 0.05, **p < 0.01. (Ptf1a-Cre; Kras, Ptf1a-Cre; Kras; Stat3, and Ptf1a-Cre;
Stat3 represent Ptf1a-Cre; KrasG12D, Ptf1a-Cre; KrasG12D, and Ptf1a-Cre; KrasG12D; Stat3f/f mice, respectively).
See also Figure S3.
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Stat3 and MMP7 in Pancreatic Ductal Adenocarcinomaof these immune subsets, these data indicate that the lack of
Stat3 signaling during initiation of Kras-driven metaplasia
decreases total inflammatory infiltration and alters immune cell
composition.
To better understand how Stat3 might contribute to meta-
plasia-associated inflammation, we determined the expression
of cytokines in pancreata from Ptf1a-Cre; KrasG12D and Ptf1a-
Cre; KrasG12D; Stat3f/f mice 1 day after caerulein. qPCR for
Stat3 target genes, including cytokines (IL-6, IL-1b, IL-11), the
inflammatory mediator ICAM1, and the prostaglandin-producing
enzyme Cox-2 (Yu et al., 2009), as well as other inflammatorymediators associated with pancreatitis (the cytokine Tnfa, and
the chemokine CCL2) (Malka et al., 2000; Marra, 2005), revealed
significantly higher levels in the pancreata of Ptf1a-Cre; KrasG12D
mice compared to those from Ptf1a-Cre; KrasG12D; Stat3f/f
mice (Figure 4B). Because immune cells present in tissue
inflammation produce cytokines (Shrivastava and Bhatia,
2010), these differences in cytokine expression may reflect the
distinct inflammatory composition observed in each genotype.
However, acini are known to represent an epithelial source of
cytokines during caerulein pancreatitis (Bhatia et al., 2002;
Blinman et al., 2000; Grady et al., 1997). To determine if theCancer Cell 19, 441–455, April 12, 2011 ª2011 Elsevier Inc. 447
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part be due to epithelial Stat3-dependent function, wemeasured
the expression of the Stat3-dependent genes IL6, IL-11, and
Cox-2 in primary cultured acini treated with caerulein isolated
from control and Ptf1a-Cre; Stat3f/fmice. Interestingly, we found
a significant decrease in expression of these factors in caerulein-
treated acini lacking Stat3 compared with control (Figure 4C).
Taken together, our data demonstrate that epithelial Stat3
modulates the initial immune response, as well as contributes
to the cytokine milieu present during initiation of Kras-driven
metaplasia.
Stat3 Supports MMP7 Expression during Kras-Driven
PanIN Development following Acute Pancreatitis
Because Stat3 appears to be critical for Kras-dependent PanIN
development, we searched for possible downstream signaling
factors supported by Stat3. Crawford et al. (2002) have previ-
ously shown that MMP7 is expressed in the exocrine compart-
ment in response to obstructive pancreatitis induced by pancre-
atic ductal ligation. Furthermore, in vitro studies in prostate and
breast cancer cell lines have implicated MMP7 as a downstream
target of Stat3 signaling (Udayakumar et al., 2002; Yuan et al.,
2008). To determine if there is an in vivo connection between
Stat3 and MMP7 during regeneration following acute pancrea-
titis or in Kras-driven metaplasia and PanIN development, we
stained for MMP7 in pancreas from control, Ptf1a-Cre; KrasG12D,
and Ptf1a-Cre; KrasG12D; Stat3f/f mice after caerulein treatment.
In the absence of damage, MMP7 was not expressed in control
mice or the normal parenchyma of Ptf1a-Cre; KrasG12D mice but
was seen in spontaneously formed PanINs (data not shown). In
control mice, MMP7 was expressed 2 days posttreatment but
absent 7 days following injection (Figures 5A and 5D). In
contrast, MMP7 expression in Ptf1a-Cre; KrasG12D mice was
detectable 2 days after caerulein treatment and remained prom-
inent 7 days postinjection (Figures 5B and 5E). This differential
MMP7 expression pattern between the genotypes mirrored
Stat3 activation profiles after pancreatitis. Intriguingly, there
was significantly less MMP7 staining, as well as MMP7 expres-
sion by qPCR, in Stat3-deficient pancreata compared to Ptf1a-
Cre; KrasG12D mice at both time points (Figures 5C and 5F–5H).
No differences were detected in the expression of other MMPs,
including MMP2, MMP3, MMP9, and MMP14 between Ptf1a-
Cre; KrasG12D and Stat3-deficient mice (Figure S4). These data
indicate that Stat3 activity regulates MMP7 expression during
ductal reprogramming in vivo, suggesting a potential role for
MMP7 in PanIN development following pancreatitis.
To test the hypothesis that MMP7 is a critical downstream
effector of Stat3 during pancreatitis-driven PanIN development,
we compared PanIN formation in Pfta1-Cre; KrasG12D mice con-
taining heterozygous or homozygous germline deletion ofMMP7
(Pfta1-Cre; KrasG12D; MMP7Het and Pfta1-Cre; KrasG12D;
MMP7KO , respectively). Unlike the effect of Stat3 deletion, we
observed no significant difference in PanIN frequency, regard-
less of MMP7 expression (Figure 5I). These results were vali-
dated using another cohort of mice based on the Pdx1 promoter
(data not shown). Therefore, whereas Stat3 supports MMP7
expression during Kras-driven neoplasia in the pancreas,
MMP7 does not appear to be a critical Stat3 effector for ductal
metaplasia and PanIN development.448 Cancer Cell 19, 441–455, April 12, 2011 ª2011 Elsevier Inc.MMP7 Expression Is Controlled by Stat3 in PDA Cells,
and MMP7 Deletion Limits Tumor Size and Metastasis
Although MMP7 signaling does not appear to be essential to
pancreatitis-induced PanIN formation, previous in vitro work
using various cancer cell lines suggests that MMP7 may play
a role in cancer progression, including metastasis (Adachi
et al., 1999; Yamamoto et al., 2001). Therefore, we examined if
the positive relationship between Stat3 and MMP7 observed
during preneoplastic initiation persists in PDA cells and whether
MMP7 itself plays a role in PDA progression and tumor biology.
First, we screened seven human PDA cell lines for MMP7
expression and found that CFPAC-1 and Colo357 expressed
MMP7 at readily detectable levels (arbitrarily determined as
absolute Ct % 35 by qPCR; Figure S5A). We treated Colo357
and CFPAC-1 cells with compound S3I-201, which inhibits
Stat3 activity by binding to the Stat3 SH2 domain and preventing
homodimerization and activation of Stat3 (Lin et al., 2009;
Siddiquee et al., 2007). A concentration-dependent decrease
in both p-Stat3 levels and MMP7 expression was observed in
Colo357 cells treated with the inhibitor (Figure 6A). CFPAC-1
cells also displayed significant reduction in both p-Stat3 and
MMP7 expression at all concentrations tested (Figure S5B), indi-
cating that Stat3 signaling dynamically controls MMP7 expres-
sion in PDA cells.
Because Stat3 is active and continues to support MMP7
expression in PDA cells, we investigated if MMP7 itself contrib-
utes to PDA biology. We analyzed the effect of MMP7 deletion
on a number of Kras-driven mouse models of PDA. First, we
observed Pdx1-CreLate; KrasG12D; MMP7KO and Pdx1-CreLate;
KrasG12D; MMP7Het animals until a censor date of 13 months
(expression pattern of Pdx-CreLate mice previously described in
Heiser et al. [2006]). We found that all Pdx1-CreLate; KrasG12D;
MMP7Hetmice developed PDA (four of eightMMP7Hetmice suc-
cumbed to PDA before censor, and the other four animals had
PDA at the time of sacrifice), whereas four of 11 Pdx1-CreLate;
KrasG12D; MMP7KO mice (36.3%) were PDA free (Figure 6B).
The highest lesion grades in these animals were PanIN 1 in one
mouse and PanIN 2 in three mice. These results suggest that
MMP7 impacts PDA progression in vivo.
Next, we performed a more extensive analysis to test at what
stage MMP7 deletion impacts PDA progression in transgenic
mice fated to develop PDA with 100% penetrance due to
pancreatic deletion of one allele of p53 (Bardeesy et al., 2006)
(Pdx1-CreLate; KrasG12D; p53f/+; MMP7Het or MMP7KO). We
found that tumors identified at the time of death in Pdx1-CreLate;
KrasG12D; p53f/+; MMP7Het mice were significantly larger than
tumors observed in Pdx1-CreLate; KrasG12D; p53f/+; MMP7KO
mice (mean diameter of 1.6 cm compared to 1.0 cm, Figures
6C–6E). Furthermore, there were clear differences in disease
stage between the MMP7Het and MMP7KO groups. Although
Pdx1-CreLate; KrasG12D; p53f/+; MMP7Het mice demonstrated
the usual stigmata of end-stage PDA in the form of ascites,
regional disease, and distant metastasis in a majority of cases,
metastasis was dramatically reduced in Pdx1-CreLate; KrasG12D;
p53f/+; MMP7KO mice (Figures 6D and 6E and Table 1; Figures
S5H and S5I). No MMP7KO mice had obvious metastasis to
lymph nodes, whereas 58% of MMP7Het mice had lymph node
involvement. Similarly, whereas only 12.5% of MMP7KO mice
had hepatic involvement, 66.7% of MMP7Het mice had liver
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Figure 5. Stat3 Regulates MMP7 Expression during Kras-Driven PanIN Development following Acute Pancreatitis
(A–F) IHC for MMP7 in pancreata from control, Ptf1a-Cre; KrasG12D, and Ptf1a-Cre; KrasG12D; Stat3f/fmice, 2 or 7 days post-caerulein injections. (A–C) Two days
post-caerulein. (D–F) Seven days post-caerulein.
(G and H) qPCR for MMP7 expression. Mean ± SD (n = 3). *p < 0.05.
(I) Alcian blue-positive lesion in total pancreas area of Ptf1a-Cre; KrasG12D; MMP7Het (n = 7) and Ptf1a-Cre; KrasG12D; MMP7KO (n = 4) mice. Mean ± SD. Scale
bars, 50 mm.
See also Figure S4.
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Stat3 and MMP7 in Pancreatic Ductal Adenocarcinomametastasis. These striking differences suggest that MMP7
contributes to PDA progression by supporting tumor size and
metastasis.
Despite the profound differences in disease staging between
the MMP7Het and MMP7KO cohorts, there was surprisingly no
difference in overall survival between mice in the two groups
(Figure S5C). Although these results may, at first glance, imply
that MMP7 loss results in increased malignancy (i.e., death
despite lower tumor burden), a more detailed analysis of the
cohorts suggested otherwise. First, despite the lack of differ-
ence in overall survival, three of nine mice with complete MMP7
loss survived beyond 36 weeks, whereas no Pdx1-CreLate;KrasG12D; p53f/+; MMP7Het mice survived beyond 35 weeks
and with the majority succumbing before 30 weeks (Figure S5C).
Also, five of nine Pdx1-CreLate; KrasG12D; p53f/+; MMP7KO mice
appeared to have died from functional obstructive disease in
the setting of relatively small primary tumors. Three mice,
including one long-term survivor (Mouse 221, 37.9 weeks, Table
S1), had a massively dilated stomach and duodenum with
a relatively small pancreatic head tumor located at the transition
point (Figures 6E; Figure S5E). Another long-term survivor
(Mouse 328, 36.1 weeks, Table S1) had biliary outlet disease
that resulted in jaundice and grossly dilated gallbladder and
common bile duct that measured 5 mm (Figures S5F andCancer Cell 19, 441–455, April 12, 2011 ª2011 Elsevier Inc. 449
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Figure 6. MMP7 Expression Is Mediated by Stat3 in PDA Cells and Contributes to Tumor Size and Metastasis
(A) Colo357 cells treated with compound S3I-201, a specific Stat3 inhibitor, or DMSO. BothMMP7 (qPCR) and p-Stat3 (western blot) expression showed dose-
dependent reduction. Mean ± SD (nR 3). **p < 0.01, ***p < 0.001.
(B) Number of Pdx1-Cre; KrasG12D; MMP7Het (n = 8) or Pdx1-Cre; KrasG12D; MMP7KO (n = 11) mice that were free of PDA found at time of death or at time of
sacrifice at censor date. *p% 0.05 (chi-square test).
(C–I) Characterization of Pdx1-Cre; KrasG12D; p53f/+; MMP7Het and Pdx1-Cre; KrasG12D; p53f/+; MMP7KOmice. (C) Size of primary tumor at death (cm). Solid bar
denotes mean. ***p < 0.001. (D) Representative photograph of disease seen in Pdx1-Cre; KrasG12D; p53f/+; MMP7Het cohort. Large pancreatic head mass is
outlined in yellow dashed line. Yellow arrow points tomesenteric lymphadenopathy. Liver nodules and ascites were also seen at necropsy in thismouse. (E) Pdx1-
Cre; KrasG12D; p53f/+; MMP7KOmouse. Yellow dashed line outlines relatively smaller pancreatic mass. Single asterisk (*) denotes massively dilated stomach, and
double asterisks (**) denote dilated proximal duodenum. Arrowhead points to transition point (located next to tumor) from dilated proximal duodenum to
decompressed distal bowel. There was no liver disease or obvious lymphadenopathy. (F and G) H&E. Histology from both genotypes is similar. (H) IHC for MMP7
Pdx1-Cre; KrasG12D; p53f/+; MMP7Het, seen in patchy distribution. (I) No MMP7 staining in Pdx1-Cre; KrasG12D; p53f/+; MMP7KO tumors. Scale bars, 100 mm.
See also Figure S5.
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Stat3 and MMP7 in Pancreatic Ductal AdenocarcinomaS5G). Four of these five MMP7KO animals did not have any
evidence of distant disease and in all likelihood would have
survived longer if not for these functional obstructions of the
gastrointestinal tract. In contrast only two of ten Pdx1-CreLate;
KrasG12D; p53f/+; MMP7Het mice had significant obstruction,
but one of these also had disseminated disease (Mouse 344,
Table S1). Finally, the potential for relatively longer survival in450 Cancer Cell 19, 441–455, April 12, 2011 ª2011 Elsevier Inc.mice with MMP7 deletion was confirmed in a second cohort of
mice utilizing Ptf1a-Cre to activate expression of mutant Kras
in the context of one deleted allele of p53 (Ptf1a-Cre; KrasG12D;
p53f/+; MMP7Het or MMP7KO). Two out of four of these Ptf1a-
Cre; KrasG12D; p53f/+; MMP7KOmice survived beyond 34 weeks,
whereas no MMP7Het mice reached even 29 weeks of age (Fig-
ure S5D). This suggests that complete loss ofMMP7may extend
Table 1. Disease Spectrum of Pdx1-Cre; KrasG12D; p53f/+ Mice with Heterozygous or Homozygous MMP7 Deletion
Median Age
at Death (week)
Mean Tumor
Size (cm)
Duo/Stomach
Obstruction
Biliary
Obstruction LN Diseasea Liver Metsa
Pdx1-Cre; KrasG12D; p53f/+; MMP7Het (n = 12) 27.5 1.6 ± 0.3 8.3% 8.3% 58.3% 66.7%
Pdx1-Cre; KrasG12D; p53f/+; MMP7KO (n = 8) 30.5 1.0 ± 0.4 37.5% 12.5% 0% 12.5%
See also Table S1. Duo, duodenum.
a p < 0.05, by chi-square test.
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Stat3 and MMP7 in Pancreatic Ductal Adenocarcinomalife span beyond the time frame observed in mice with intact
MMP7 activity.
Although we observed significant differences in disease stage
in our studies, we saw no differences in tumor histology in any of
the cohorts we followed. All mice analyzed developed tumors
that can be generally described asmoderately to poorly differen-
tiated (Figures 6F and 6G), regardless of MMP7 status. Of
interest, MMP7 staining in Pdx1-CreLate; KrasG12D; p53f/+;
MMP7Het mice was seen in a patchy distribution throughout
the tumor localizing to the luminal surfaces of glandular struc-
tures, consistent with staining patterns seen in human PDA (Fig-
ure 6H; Figure S5J). As expected, no MMP7 expression was
found in PDA observed in Pdx1-CreLate; KrasG12D; p53f/+;
MMP7KO mice (Figure 6I).
Serum MMP7 Predicts Metastatic Disease in Humans
Previous studies with human PDA samples have shown that
MMP7 levels correlate with tumor stage (Fukushima et al.,
2001; Yamamoto et al., 2001) and overall survival (Jones et al.,
2004; Yamamoto et al., 2001). To study the potential utility of
serum MMP7 to provide preoperative clinical information, we
accessed the University of Utah Huntsman Cancer Institute
database and identified 101 patients with PDA in whom serum
MMP7 levels were measured.
When patients were grouped by tumor class, all patients
without lymph node involvement (N0) had serum MMP7 levels
below 20.2 ng/ml, whereas patients with metastatic disease
(M1; stage IV; please see Table S2 for the TNM staging systemA B
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Figure 7. Serum MMP7 Level Predicts Metastatic Disease in Humans
(A andB) SerumMMP7 levels in patients with PDA.Mean ± SEM. (A) Patients strati
involvement; M1, distant metastasis. **p < 0.01. (B) Patients stratified by stage.
(C) Kaplan-Meier curves showing significantly lower survival in patients with ele
***p < 0.0001 by Mantel-Cox log rank test.
See also Tables S2–S5.for PDA) had significantly higher levels (Figures 7A and 7B).
However, regional lymph node involvement (N1; stage IIB) did
not correlate to MMP7 levels, even though some patients with
N1 did have MMP7 levels above 20.2 ng/ml.
Serum MMP7 levels were a significant predictor of survival,
independent of whether MMP7 was used as a continuous
or discrete variable, with 20 ng/ml as the threshold value
(Table S3). With one exception, patients with MMP7 above this
value had higher than expected risk of earlier death. Patients
with PDA with MMP7 serum levels below 20 ng/ml had a median
survival of 329 days, whereas those with levels above the
threshold had amedian survival of 114.5 days (Table S3). Kaplan-
Meier survival analysis confirmedsignificantly decreased survival
in the high-serum MMP7 group (Figure 7C; Table S4).
We found that tumor stage, distant metastasis, tumor resect-
ability, and whether the patient received treatment were all
favorable predictors of survival in univariate analyses (Table
S3). Interestingly, serum MMP7 levels remained a significant
predictor of survival, even after stratifying for treatment type
and tumor class in multivariate analysis (Table S5). These data
suggest that serum levels of MMP7 may be a useful clinical
tool to predict survival in patients suffering from PDA.
DISCUSSION
Stat3 Contributes to Pancreatic Cancer Initiation
The reprogramming of normal pancreatic cells into those with
a neoplastic fate is a key step in PDA initiation and deserves*
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significantly alters pancreatic plasticity, and can drive acinar
cells toward a ductal fate capable of giving rise to PDA (De La
et al., 2008; Guerra et al., 2007; Habbe et al., 2008; Morris
et al., 2010). Chronic pancreatitis is a potent risk factor for PDA
development in humans, and pancreatitis induction in Kras-
driven mouse models of PDA has revealed that inflammatory
damage can promote (Guerra et al., 2007) and/or accelerate
(Carriere et al., 2009; Morris et al., 2010) PanIN and PDA forma-
tion. Kras appears to drive acinar-derived PanIN development
following pancreatitis by blocking normal regeneration in favor
of a persistently dedifferentiated, ductal state that is permissive
for PanIN formation. This finding suggests that assuming a dedif-
ferentiated state may be a rate-limiting step during Kras-driven
neoplastic reprogramming in the pancreas. In this study we
induced both acute and chronic pancreatitis in transgenic mice
expressing an oncogenic Kras allele in the context of epithelial
Stat3 deficiency and found that these animals formed signifi-
cantly fewer PanINs and retained more normal parenchyma
than mice that had intact Stat3 signaling. These data implicate
Stat3 as an important accomplice to Kras in diverting normal
regeneration and maintaining the dedifferentiated ductal state
initiated by pancreatitis.
Also, we found that in the presence of mutant Kras, Stat3
supports metaplasia-associated inflammation in a manner that
is distinct from what is observed during normal pancreatic
regeneration. We found that pancreatic epithelial Stat3 deletion
results in attenuated inflammatory cell infiltration and reduced
expression of proinflammatory cytokines. We speculate that
the reduced cytokine expression in Ptf1a-Cre; KrasG12D; Stat3f/f
mice is due to a combination of cell-autonomous effects of
Stat3 deletion in the pancreatic epithelium and a reduced
number of infiltrating inflammatory cells. Therefore, our data
suggest that Stat3 plays both a critical cell autonomous role
in maintaining the proliferative, persistently dedifferentiated
epithelial state permissive for PDA precursor formation and
also contributes to metaplasia-associated inflammation. Further
work is required to enhance our understanding of howStat3 acti-
vation contributes to immune cell recruitment. Also, aberrant
cytokine expression has been shown to enhance tumorigenesis
(Ernst et al., 2008), and additional studies are required to deter-
mine how epithelial-derived, Stat3-dependent cytokines, and
those produced by infiltrating immune cells, contribute to PanIN
development and PDA progression. Another unresolved ques-
tion concerns the roles of the distinct immune cell types infil-
trating during Kras-driven pancreatitis-induced PanIN formation.
Summarily, these findings demonstrate that Stat3 activation in
pancreatic epithelial cells plays a significant role linking pancre-
atitis and PDA initiation in vivo.
Although we have focused our efforts on caerulein-induced
pancreatitis, it would be interesting to investigate whether
Stat3 signaling is also important in other models of pancreatic
damage. These include hereditary pancreatitis caused by
a missense mutation in the trypsin gene (PRSS1) (Archer et al.,
2006) or cytokine-induced pancreatitis caused by ectopic
expression of interleukin-1b (Marrache et al., 2008). Another
potential avenue of investigation is whether Stat3 interacts with
the primary cilia, which are the cellular appendages known to
regulate Hedgehog signaling. The elimination of the primary cilia452 Cancer Cell 19, 441–455, April 12, 2011 ª2011 Elsevier Inc.produces pancreatic lesions that resemble those found in
patients with chronic pancreatitis or cystic fibrosis (Cano et al.,
2006).
MMP7 Contributes to PDA Size and Metastasis
Similar to findings obtained from other organs, we confirmed that
Stat3 controls MMP7 expression in PDA cell lines. In this study
we used several genetic models to demonstrate that MMP7
has a functional role in PDA progression by predominantly
affecting tumor size andmetastasis. Furthermore, we and others
have found that MMP7 levels correlate with both tumor stage
and survival (Jones et al., 2004; Yamamoto et al., 2001).
The mechanisms by which MMP7 affects PDA tumor size and
metastasis need to be clarified in future studies. However, based
on the number of substrates that MMP7 can act upon, multiple
pathways may be involved. Epithelial basement membrane
and extracellular components are MMP7 targets (Remy et al.,
2006), suggesting that PDA cells lacking in MMP7 may not be
able to escape the primary tumor site. Another possibility is the
need for MMP7 activity for proper seeding at a potential meta-
static site (Lynch et al., 2005). MMP7 can also influence the
immune system by controlling chemokine gradients to affect
neutrophil infiltration (Li et al., 2002). Such effects on immune
cells may help propagate the feed-forward loop established by
aberrant Stat3 signaling and perhaps contribute to the exuberant
desmoplastic reaction seen in PDA. Finally, MMP7 may also
affect the tumor angiogenic response because MMP7 knockout
mice develop prostate cancers that have fewer tumor blood
vessels that are also smaller in diameter (Littlepage et al.,
2010). Future studies will have to address the exact mechanisms
by which MMP7 functions in the context of PDA, a feat that is
complicated by the observation that MMP7 is expressed only
regionally throughout the tumors, suggestive of local differences
in the malignant nature of individual cells throughout a tumor.
The concept of the ‘‘invasive front’’ that possesses more malig-
nant and metastatic potential was recently reviewed (Christofori,
2006), and it is conceivable that metastases first arose from
these nests of MMP7-positive cells. This highly speculative
concept is an intriguing idea that could be tested with the
development of lineage-tracing systems dependent on MMP7
expression.
Clinical Implications
Our study implicates both Stat3 and MMP7 as potential targets
for adjuvant therapy development. The involvement of Stat3 in
PDA initiation highlights the potential of Stat3 as a therapeutic
target for preventing inflammation-associated PDA formation
at the earliest stage. A recent study confirmed the potential utility
of targeting the Stat3 pathway by showing that JAK2 kinase inhi-
bition and Stat3 knockdown both abrogated tumor xenograft
growth in a variety of solid-organ cancers, including pancreas
(Hedvat et al., 2009). The role of Stat3 in pancreatic cancer
progression and metastasis in vivo requires future studies,
though there are in vitro data showing the importance of Stat3
to PDA cell growth (Scholz et al., 2003).
The significant reduction ofmetastatic disease seen inMMPKO
mice has profound translational implications for patients with
PDA. Currently, only about 20% of patients undergoing PDA
resections survive beyond 5 years (Yeo et al., 1995). Our study
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therapy to block disease progression after resection. However,
previous clinical trials involving MMP inhibitors have yielded
disappointing results (Coussens et al., 2002). Part of the failure
may have been because clinical studies enrolled patients with
advanced-stage cancers, whereas successful results in mice
occurred with treatment starting at earlier disease stage. It is
possible that the beneficial effect of MMP7 inhibition is greater
in prevention of progression of subclinical disease as in the adju-
vant setting than in reduction of size of gross metastatic disease.
Furthermore, some MMPs may have tumor-suppressive effects
that could be compromised by nonspecific pan-MMP inhibition
(Kessenbrock et al., 2010), suggesting that targeting specific
MMPs may be a more effective therapeutic strategy.
Using a large repository of serum samples from human
patients with PDA, we found that serum MMP7 levels signifi-
cantly correlate with metastatic disease and survival, albeit
with low sensitivity. This finding may be able to help guide
patients and physicians with diagnostic and prognostic informa-
tion to predict the survival benefit before patients undergo PDA
resections. These considerations are particularly important
because pancreatic resections entail complicated and lengthy
operations that not only require months of recovery but carry
significant risk for complications and death (Winter et al.,
2006). Serum MMP7 levels might also be considered in deci-
sions regarding postoperative adjuvant chemoradiation therapy
after resection.
Recent sequencing studies have revealed that PDA cells
possess a bewildering array of mutations (Jones et al., 2008).
In order to develop improved therapeutics, it is essential to iden-
tify critical signaling nodes that PDA cells depend upon for
growth and spread. Our study implicating Stat3 and MMP7 as
key mediators of PDA initiation and progression not only points
to potentially novel targets for future therapies but also demon-
strates the utility of the Kras/inflammation system as an in vivo
model to dissect complex signaling pathways important to
pancreatic carcinogenesis.
EXPERIMENTAL PROCEDURES
Mice
Experimental animals were generated by crossing Ptf1a-Cre (Dr. C. Wright,
Vanderbilt University, Nashville, TN) (Kawaguchi et al., 2002), Pdx1-CreLate
(Dr. P. Herrera, University of Geneva Medical School, Geneva) to mice
expressing LSL-KrasG12D (Dr. D. Tuveson, Cancer Research UK Cambridge
Research Institute, Cambridge) (Hingorani et al., 2003), and Stat3flox (Takeda
et al., 1998), MMP7KO (Crawford et al., 2002), or p53flox (Bardeesy et al.,
2006). Transgenic mice were in a mixed background. Littermates not express-
ing Cre as well as Ptf1a-Cre and Stat3f/+ mice of the same age were used as
control. All mouse experiments were performed under the approval of the
UCSF IACUC.
Caerulein Treatment
Acute pancreatitis was induced by intraperitoneal (i.p.) caerulein injections
(50 mg/kg; Sigma): one injection per hour for six injections and repeated
2 days later. Chronic pancreatitis was induced by 3 or 4 weeks of caerulein
injections as previously described (Martinez-Romero et al., 2009; Strobel
et al., 2007) with the following modifications. The 3-week protocol was six
hourly i.p. injections (50 mg/kg) per day, 3 days per week, for 3 weeks. The
4-week protocol was one i.p. injection per day (70 mg/kg), 5 days per week,
for 4 weeks. Animals were sacrificed 3 days after the final injection in the
both chronic pancreatitis models.Primary Acinar Tissue Culture
Primary acinar tissue cultures were prepared by modifying published proto-
cols (Means et al., 2005). Transdifferentiation events were induced by addition
of TGF-a (50 ng/ml; Chemicon International). Cultures were maintained in
a 37C and 5% CO2 incubator for 5 days with medium replaced on days 1
and 3. Cultured acini were treated with 10 nM caerulein for 20 hr.Human Serum MMP7 Measurements
Serum samples were obtained from 101 consecutive subjects with histologi-
cally or cytologically confirmed PDA for whom pretreatment serum samples
were available. The cohort consisted of 46women (median age 69 years, range
43–86) and 55 men (median age 64 years, range 42–86). Whole blood was
collected prior to the patients receiving treatment. Serological MMP7
measurements were performed by ELISA (Quantikine Human MMP7 (total)
Immunoassay; R&D Systems) according to the manufacturer recommenda-
tions except that serum samples were diluted 4-fold with sample diluent. All
human subjects gave informed consent, and the study was approved by the
Institutional Review Board of the University of Utah.Statistical Analyses
Data are presented as mean ± SD or SEM as noted and subjected to unpaired
Student’s t test, unless otherwise noted. A p value < 0.05 was considered to be
significant. Statistical analysis of clinical variables and serum MMP7 level
methods are described in Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, five tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:
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